S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Conformis Stock Forecast, Price & News

-0.01 (-1.59%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
829,889 shs
Average Volume
834,266 shs
Market Capitalization
$115.19 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive CFMS News and Ratings via Email

Sign-up to receive the latest news and ratings for Conformis and its competitors with MarketBeat's FREE daily newsletter.

Conformis logo

About Conformis

ConforMIS, Inc. is a medical technology company, which engages in the development, manufacture, and sale of joint replacement implants. It operates through the following geographical segments: United States; Germany; and Rest of the World. The firm's products include iUni, iDuo, iTotal CR, and iTotal. The company was founded by Philipp Lang in 2004 and is headquartered in Billerica, MA.


See More Headlines

Industry, Sector and Symbol

Surgical appliances & supplies
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$68.76 million
Book Value
$0.12 per share


Net Income
$-24.29 million
Pretax Margin




Free Float
Market Cap
$115.19 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

1.80 out of 5 stars

Medical Sector

851st out of 1,415 stocks

Surgical Appliances & Supplies Industry

17th out of 28 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Conformis (NASDAQ:CFMS) Frequently Asked Questions

Is Conformis a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Conformis in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Conformis stock.
View analyst ratings for Conformis
or view top-rated stocks.

How has Conformis' stock price been impacted by Coronavirus?

Conformis' stock was trading at $0.66 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, CFMS stock has decreased by 6.2% and is now trading at $0.6190.
View which stocks have been most impacted by COVID-19

When is Conformis' next earnings date?

Conformis is scheduled to release its next quarterly earnings announcement on Wednesday, March 2nd 2022.
View our earnings forecast for Conformis

How were Conformis' earnings last quarter?

Conformis, Inc. (NASDAQ:CFMS) announced its quarterly earnings results on Wednesday, November, 3rd. The medical instruments supplier reported ($0.07) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.07). The medical instruments supplier earned $14.25 million during the quarter, compared to the consensus estimate of $14.08 million. Conformis had a net margin of 6.86% and a trailing twelve-month return on equity of 8.19%. During the same period last year, the business earned ($0.09) earnings per share.
View Conformis' earnings history

What price target have analysts set for CFMS?

1 brokers have issued 12-month price objectives for Conformis' stock. Their forecasts range from $2.00 to $2.00. On average, they expect Conformis' stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 223.1% from the stock's current price.
View analysts' price targets for Conformis
or view top-rated stocks among Wall Street analysts.

Who are Conformis' key executives?

Conformis' management team includes the following people:
  • Mark A. Augusti, President, Chief Executive Officer & Director
  • Gary Maingot, Senior Vice President-Operations
  • Robert Howe, CFO, Treasurer & Principal Accounting Officer (LinkedIn Profile)
  • Marc Quartulli, Vice President-Clinical Affairs & Market Access
  • John Slamin, Senior Vice President-Product Engineering

What is Mark Augusti's approval rating as Conformis' CEO?

15 employees have rated Conformis CEO Mark Augusti on Glassdoor.com. Mark Augusti has an approval rating of 55% among Conformis' employees. This puts Mark Augusti in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Conformis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Conformis investors own include Advanced Micro Devices (AMD), Martin Midstream Partners (MMLP), Micron Technology (MU), NVIDIA (NVDA), Trevena (TRVN), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Alibaba Group (BABA) and AT&T (T).

When did Conformis IPO?

(CFMS) raised $135 million in an initial public offering on Wednesday, July 1st 2015. The company issued 9,000,000 shares at $14.00-$16.00 per share. J.P. Morgan and Deutsche Bank Securities acted as the underwriters for the IPO and Wells Fargo Securities and Canaccord Genuity were co-managers.

What is Conformis' stock symbol?

Conformis trades on the NASDAQ under the ticker symbol "CFMS."

How do I buy shares of Conformis?

Shares of CFMS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Conformis' stock price today?

One share of CFMS stock can currently be purchased for approximately $0.62.

How much money does Conformis make?

Conformis has a market capitalization of $115.19 million and generates $68.76 million in revenue each year. The medical instruments supplier earns $-24.29 million in net income (profit) each year or ($0.03) on an earnings per share basis.

How many employees does Conformis have?

Conformis employs 259 workers across the globe.

What is Conformis' official website?

The official website for Conformis is www.conformis.com.

Where are Conformis' headquarters?

Conformis is headquartered at 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821.

How can I contact Conformis?

Conformis' mailing address is 600 TECHNOLOGY PARK DRIVE, BILLERICA MA, 01821. The medical instruments supplier can be reached via phone at (781) 345-9001, via email at [email protected], or via fax at 781-345-0147.

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.